source
- Biogen reports mixed Alzheimer’s trial results as industry sees new startup launchesBiogen released data from its Alzheimer’s program that showed mixed outcomes, indicating some signals but also setbacks. The weekly newsletter also highlighted the launch of two new biotech startu…
- Compounders still supply about 20% of US GLP-1 weight-loss market despite FDA crackdown and shortagesA recent Gallup survey shows that while the number of Americans taking GLP-1 weight‑loss drugs has nearly quadrupled over the past two years, roughly one in five are using cheaper, non‑FDA‑approved…